Apogenix GmbH

General information
Apogenix GmbH
Im Neuenheimer Feld 584
69120 Heidelberg, Baden-Württemberg
Germany

Contact person: Thomas Hoeger, Chief Executive Officer
Company main phone: +49 (6221) 586080
Company main fax:  +49 (6221) 5860810
Website:  https://www.apogenix.com
Year founded:2005
Source of foundation:Spin-off from public institution / NPO
Name of foundation source:German Cancer Research Center, Heidelberg
Corporate description / mission:
Apogenix develops innovative protein therapeutics for the treatment of solid tumors, malignant hematological diseases, and COVID-19. The company's Asunercept is a CD95 ligand inhibitor that is currently in clinical development for the treatment of cancer. It shows the potential for broad application in the treatment of solid tumors, malignant hematological diseases, and viral infections, such as COVID-19.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Immunotherapy
  • Proteins
  • Small molecules
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Skin and subcutaneous tissue / dermatology
Business model:
  • R&D
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:5
Phase I:2
Phase II:1
Phase III:1
Description of products:
Asunercept
Technology used:
HERA-Ligand Technology
Collaborations & Clients
Partnering strategy / collaborations:
Apogenix is exploring partnerships with pharmaceutical and biotechnology companies as well as collaborations with leading academic institutions in order to advance the preclinical and clinical development and commercialization of its proprietary drug candidates targeting members of the TNF superfamily and TNF receptor superfamily.
X